Alkermes plc (ALKS) Cash Flow Statement

The OCF/NI ratio swung from 289.79 in 2026Q2 to 2.49 in 2026Q1, driven by a $160.3M working capital outflow in Q1 versus a $12.5M inflow in Q2. This suggests that reported net income is heavily influenced by non-cash items and working capital timing, rather than a stable conversion of earnings to cash. Investors should monitor whether the 2026Q2 net income of $501K is artificially depressed by one-time charges, as operating cash flow of $145.2M appears robust.

Excluding the anomalous 2026Q1, FCF margins have been consistently above 20% for the past five quarters, with 2025Q4 reaching 44.2%. This suggests that the underlying business generates strong cash flow, but the quarterly volatility in working capital can distort the trend. The 2026Q1 negative FCF of -$169.8M appears to be a timing issue rather than a structural deterioration, as subsequent quarters recovered sharply.

CapEx has remained consistently low, ranging from 0.0% to 4.4% of revenue, which is typical for a biotech with outsourced manufacturing. This low capital intensity means that the company can sustain high FCF margins without heavy reinvestment, but it also implies that growth may depend on acquisitions or partnerships rather than organic capacity expansion. The recent spin-off of Mural Oncology may further reduce capital needs, but investors should watch for any increase in CapEx if the company invests in new manufacturing capabilities.

The large working capital swings appear to be driven by timing of receivables and payables, possibly related to the Janssen royalty arbitration and channel loading for Lybalvi. The 2026Q1 outflow of $160.3M was the primary cause of the negative operating cash flow, but the subsequent recovery in Q2 suggests this was a temporary disruption. Investors should monitor whether these swings persist, as they could indicate aggressive revenue recognition or inventory management practices.

The company has not paid dividends in any of the last ten quarters, and buybacks have been sporadic, with significant repurchases in 2024Q3 ($115.6M) and 2024Q2 ($85.3M) but none in 2026Q2. This inconsistency may indicate that management is conserving cash for potential bolt-on acquisitions or to buffer against royalty arbitration uncertainty. The $1.1B cash pile provides ample flexibility, but the lack of consistent capital return suggests a strategic pivot toward pipeline investment.

The cumulative OCF/NI ratio of 1.73 over the period suggests that the company's earnings quality is high, with cash conversion exceeding 100%. However, this divergence is partly due to non-cash charges like depreciation and stock-based compensation, which are added back to operating cash flow. The 2026Q2 net income of $501K is an outlier, likely due to one-time items, but the underlying cash generation remains robust. Investors should focus on operating cash flow rather than net income when assessing the company's financial health.